CSF2 and neoplasm: Additional TAVs may include adjuvants such as Interferon-α (IFN-α) or a granulocyte-macrophage colony-stimulating factor (GM-CSF), which are particularly important in enhancing the host’s response against tumor-derived antigens or recombinant neoantigens.